Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec 16:15:118.
doi: 10.1186/s12935-015-0270-5. eCollection 2015.

Reduced IL-33 plasma levels in aplastic anemia

Ming Sun  1 , Hai-Feng Ma  1 , Ye-Yun Che  1 , Xin Cui  2
Affiliations

Reduced IL-33 plasma levels in aplastic anemia

Ming Sun et al. Cancer Cell Int. .

Abstract

Background: In this study, we aim to evaluate the balance of interleukin (IL)-33 and its soluble receptor sST2 in patients with aplastic anemia (AA).

Methods: Plasma IL-33, IL-17 and sST2 levels were measured in patients with active AA (n = 31), AA in remission (n = 29) and in healthy subjects (n = 30), using enzyme linked immunosorbent assays (ELISAs).

Results: The results showed that sST2 and IL-17 levels were significantly elevated in patients with active AA when compared to control subjects, but IL-33 levels were significantly lower in AA patients, which resulted in elevated sST2/IL-33 ratios in patients with active disease. During remission stages, the levels of these cytokines were comparable to those of healthy controls.

Conclusions: The elevated levels of sST2/IL-33 in the plasma during active stages of the disease suggest a possible role in the pathogenesis and course of AA.

Keywords: Aplastic anemia; Cytokines; Interleukin 17; Interleukin 33; sST2.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Plasma expression of IL-33 and sST2 in AA and controls. Plasma concentrations of IL-33 in AA patients with active disease (22.7 ± 13.7 pg/ml) were found to be significantly lower than those of healthy controls (45.8 ± 24.6 pg/ml, P < 0.01) and AA patients in remission (36.8 ± 29.5 pg/ml, P < 0.01) (a). Plasma sST2 levels of AA patients with active disease (1370.1 ± 530.3 pg/ml) were significantly higher compared with healthy controls (903.7 ± 329.3 pg/ml, P < 0.01) and patients in remission (1331.8 ± 454.3 pg/ml, P < 0.01) (b)
Fig. 2
Fig. 2
The ratio of sST2/IL-33 in normal control and AA patients. # P < 0.05, active AA vs controls. *P < 0.05, active AA vs AA in remission
Fig. 3
Fig. 3
Plasma expression of IL-17 in AA and controls. # P < 0.05, active AA vs controls. *P < 0.05, active AA vs AA in remission
Fig. 4
Fig. 4
The correlation between IL-17 and IL-33 or sST2 in active AA patients. There was no correlation between IL-17 and IL-33 (r2 = −0.0139, P = 0.5275; N = 31; a) or sST2 (r2 = −0.0445, P = 0.2544; N = 31; b) expression in active AA patients
See this image and copyright information in PMC

References

    1. Brodsky RA, Jones RJ. Aplastic anaemia. Lancet. 2005;365:1647–1656. doi: 10.1016/S0140-6736(05)66515-4. - DOI - PubMed
    1. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509–2519. doi: 10.1182/blood-2006-03-010777. - DOI - PMC - PubMed
    1. Nakao S. Immune mechanism of aplastic anemia. Int J Hematol. 1997;66:127–134. doi: 10.1016/S0925-5710(97)00032-7. - DOI - PubMed
    1. Zoumbos NC, Gascon P, Djeu JY, Young NS. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci USA. 1985;82:188–192. doi: 10.1073/pnas.82.1.188. - DOI - PMC - PubMed
    1. Nistico A, Young NS. gamma-Interferon gene expression in the bone marrow of patients with aplastic anemia. Ann Intern Med. 1994;120:463–469. doi: 10.7326/0003-4819-120-6-199403150-00003. - DOI - PubMed

LinkOut - more resources